相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1843
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Researchers at Case Western Reserve University found that vitamin B3 derivatives NMN, NR, and NAM may help pancreatic cancer cells survive and resist chemotherapy. - In laboratory and animal models, the supplements shielded cancer cells against oxaliplatin, 5-fluorouracil, and gemcitabine, allowing tumors to survive otherwise fatal doses. - The study, published in Cancer Letters, found NMN had the greatest impact on chemotherapy resistance, while NR had a smaller effect. - Researchers urge oncology teams to routinely screen cancer patients for supplement use and call for further studies on NAD+ precursor interactions with cancer therapies.
- AN2 Therapeutics announced plans to advance oral epetraborole into a Phase 2 proof-of-concept study for adults with phlebotomy-dependent polycythemia vera, a blood cancer affecting approximately 155,000 people in the U.S. - The decision is supported by clinical evidence showing epetraborole consistently demonstrated early, controlled, sustained, and dose-dependent hematocrit reductions across multiple clinical populations including healthy volunteers and NTM lung disease patients. - The Phase 2 trial is expected to begin in the third quarter of 2026 in India, with potential data readouts as early as fourth quarter 2026 and throughout 2027. - Epetraborole operates through a potentially differentiated mechanism targeting globin synthesis rather than heme synthesis, offering red-cell selectivity while sparing white blood cells and platelets.
- A phase II randomized clinical trial led by Penn State and USC researchers demonstrated that targeted therapy for the less-impaired arm significantly improved movement and control in chronic stroke survivors with severe paralysis. - The study of 53 participants showed that training the "good" arm resulted in 12% faster completion of dexterity tests, with improvements persisting for at least six months after therapy ended. - This first-of-its-kind evidence-based intervention challenges traditional stroke rehabilitation by addressing the often-overlooked 10-25% loss of motor coordination in the less-impaired arm. - The findings, published in JAMA Neurology, could meaningfully enhance quality of life and reduce caregiver burden for stroke survivors who rely on their functional arm for daily tasks.
- The phase II BALANCE trial validated PAM50 as the first predictive biomarker for hormone therapy response in recurrent prostate cancer, identifying patients with luminal B tumors who benefit significantly from apalutamide treatment. - Patients with luminal B tumors showed 72.4% five-year biochemical progression-free survival with apalutamide versus 53.9% with placebo, while non-luminal B patients saw no benefit from hormone therapy. - The genomic test could revolutionize treatment personalization by recommending hormone therapy only for responsive patients while sparing others from unnecessary side effects. - Results were so definitive that researchers believe a phase III confirmatory trial would be unethical, suggesting rapid clinical implementation of PAM50 testing in recurrent prostate cancer management.
